Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours

Advanced Solid Tumours Clinical Trial

Official title:

A Phase I Study Evaluating the Proton Pump Inhibitor Pantoprazole in Combination With Doxorubicin for Advanced Cancer Patients With an Extension Cohort of Patients With Solid Tumours

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01163903
• Other study ID #: DDP-IT-01
• Status: Completed
• Phase: Phase 1
• First received: July 13, 2010
• Last updated: July 14, 2015
• Start date: July 2010
• Est. completion date: May 2015

Study information

• Verified date: July 2015
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Ethics Review CommitteeCanada: Health Canada
• Study type: Interventional

Clinical Trial Summary

This is a single-centre, open label, dose finding, phase I study to determine the recommended phase II dose (RP2D) for the combination of doxorubicin and pantoprazole in patients with advanced tumours and no standard treatment options. A minimum of 3 patients will be enrolled per dose level and intra-patient dose escalation is not permitted. Once the RP2D has been identified, six additional patients with metastatic solid tumours will be treated at the RP2D to confirm its tolerability.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: May 2015
• Est. primary completion date: March 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients must have histologically or cytologically proven advanced solid tumours for whom no standard anticancer therapy exists

2. Measureable and non-measureable disease are both eligible, but disease must be evaluable as defined by RECIST 1.1.

3. Patients >18 years old

4. At least 21 days since last chemotherapy regimen and/or radiotherapy

5. Recovery from all reversible adverse events of previous anticancer therapies to baseline or to grade < or =1, except for alopecia.

6. Patients must have documented evidence of disease progression on prior systemic therapy.

7. ECOG Performance Status of 0 or 1

8. Adequate cardiovascular function and no history of serious cardiac diseases (see Exclusion criteria for definition) Left ventricular ejection fraction > 50% by multi-gated nuclear angiogram

9. Patient consent must be obtained according to Institutional REB requirements. The patient must sign the consent form prior to registration.

10. Patients must be accessible for treatment and follow-up.

11. Previous Therapy

1. Chemotherapy: Patients can have had limited exposure to prior anthracyclines defined as no more than a total dose of 240 mg/m2 of doxorubicin or 300 mg/m2 of epirubicin (e.g. as received in the AC x 4 or FEC x 3 adjuvant regimens). Patients with prior exposure to other cardiotoxic anticancer drugs (e.g. mitoxantrone) are not eligible.

2. Radiation: Patients may have had prior radiation therapy (including that to the breast or chest wall) provided that has not exceeded 25% of the bone marrow reserve.

3. Previous Surgery: Previous surgery is permitted provided that wound healing has occurred.

4. Hormonal Therapy: Patients may have had prior hormonal therapy. All hormonal agents must be discontinued at least 3 weeks prior to study entry.

12. Laboratory Requirements (must be done within 7 days prior to registration)

1. Neutrophil count (ANC) > or = 1.5 x 10^9/L

2. Hemoglobin > or = 90 g/L

3. Platelet count > or = 100 x 10^9/L

4. Bilirubin <1.5 x UNL

5. AST or ALT < or = 2 x UNL

6. Creatinine < or = 1.5 x UNL or creatinine clearance > or = 50mL/min

Exclusion Criteria:

1. Patients who have previously received more than 240 mg/m2 doxorubicin or 300 mg/m2 epirubicin.

2. Patients receiving concurrent treatment with experimental drugs or anti-cancer therapy.

3. Patients who are receiving drugs that are known to interact with pantoprazole, including:

1. The anti-fungal agents fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole;

2. The antiviral agents: atazanavir, delavirdine, indinavir, nelfinavir, raltegravir, saquinavir, tipranavir;

3. The anticoagulant agents: clopidogrel, dabigatran;

4. The immunosuppressive agent: mycophenolate

5. The anti-inflammatory agent: mesalamine

4. Patients who are receiving oral pantoprazole or other PPI inhibitors may participate if these agents are discontinued at least 7 days before trial entry.

5. Patients with untreated brain or meningeal metastases. (MR or CT scans are not required to rule this out unless there is a clinical suspicion of CNS disease). Patients with treated and stable brain metastases are eligible providing that they have radiological evidence of disease stabilization of at least 3 months duration and are asymptomatic.

6. Patients who have a history of clinically significant cardiac disease, including:

1. Unstable angina/ acute coronary syndrome

2. Congestive heart failure

3. Myocardial infarction within the past year

4. Clinically significant arrhythmia

5. Pericarditis or myocarditis

6. Symptomatic valvular disease Patients with well-controlled hypertension, uncomplicated mitral valve prolapsed or other stable cardiac conditions are eligible.

7. Patients with active or uncontrolled infections or with serious illnesses or medical conditions that would not permit the patient to be managed according to the protocol.

8. Patients with a known bleeding disorder. Patients who are on stable anticoagulation with warfarin or s.c. heparin products are eligible. Patients receiving clopidogrel are excluded.

9. Patients unable or unwilling to give written, informed consent prior to study participation.

10. Women who are pregnant or nursing.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Advanced Solid Tumours

Intervention

Drug:
• pantoprazole sodium for injection
Single 3-weekly doses of pantoprazole using the following dose escalation scheme for successive groups of patients: 80, 160, 240 and 320mg i.v. of pantoprazole to be given every 3 weeks, 30-60 (±5) minutes prior to doxorubicin. Treatment will be repeated on Day 1 of a 21-day cycle until radiographic or symptomatic progression or unacceptable toxicity or a maximum of 4 cycles (for patients who have received prior anthracyclines), and up to 8 cycles (for those with no prior exposure to anthracyclines).
• doxorubicin hydrochloride injection
60 mg/m2, IV, scheduled on day 1 of every 3-week interval, 30-60 (±5) minutes after pantoprazole administration.

Locations

Country	Name	City	State
Canada	Princess Margaret Hospital	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
University Health Network, Toronto	Princess Margaret Hospital, Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determination of recommended phase II dose (RP2D) of pantoprazole given with doxorubicin at 60mg/m2	To determine the recommended phase II dose (RP2D) of pantoprazole given with doxorubicin at 60mg/m2 when administered to adult patients with advanced solid tumours.	Treatment until documented progression or up to 8 21-day cycles (4 cycles if prior anthracyclines received). All patients followed for late toxicities, every 3 months for 1 year or until all drug related toxicities are resolved/become unrelated.	Yes
Secondary	Characterize the safety and tolerability of the combination by determining dose-limiting toxicities (DLTs). Toxicities evaluated and graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.	Three or 6 patients will be treated per cohort for at least one cycle (21 days per cycle). If two patients experience DLTs, then accrual will stop at that level, and the next lower dose level in which six patients have been treated with no or only 1 DLT will be declared the RP2D. Once the RP2D has been identified, six additional patients will be treated at the RP2D to confirm its safety and tolerability. Patients will be assessed for toxicities using the overall safety profile as per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.	Treatment until documented progression or up to 8 21-day cycles (4 cycles if prior anthracyclines received). All patients followed for late toxicities, every 3 months for 1 year or until all drug related toxicities are resolved/become unrelated.	Yes
Secondary	Assess the preliminary anti-tumour activity of the doxorubicin/pantoprazole by combination in patients with advanced solid tumours, by evaluating tumour response rate.	Response Evaluation Criteria in Solid Tumours (RECIST) will be used to determine radiological tumour response for measurable disease and disease progression. Changes in only the largest diameter (unidimensional measurement) of the tumour lesions are used in the RECIST criteria. Any radiological change should be confirmed using a second follow-up scan, 6 or more weeks later. For response there must be no new lesions and no evidence of progression of non-measurable lesions.	Radiologic evaluation (CT scan of chest, abdomen and pelvis) performed every 9 weeks	No
Secondary	Evaluate the pharmacokinetics of doxorubicin and pantoprazole when given in combination by collecting venous blood samples at various timepoints throughout study drug administration.		Blood samples just before and at the end of pantoprazole and doxorubicin administration, and at 1, 2, 4, 8, 24, 48 and 72 hours after (first or second) drug administration for evaluation of serum levels of doxorubicin and pantoprazole	No
Secondary	Evaluate (in selected patients with lesions amenable to biopsy) the influence of pantoprazole on distribution of doxorubicin in tumour tissue. Tumour tissue extracted after administration of doxorubicin/pantoprazole.	Two cores of tumour tissue will be extracted within 24-48 hours of administration of doxorubicin and pantoprazole;1 core will be fixed for routine pathological examination and the 2nd will be fresh frozen. The latter will be sectioned in the experimental pathology laboratory and will be stained with antibodies which recognize tumour blood vessels and regions of hypoxia. Distribution of doxorubicin (which is fluorescent) in relation to the blood vessels in tumours, and in relation to hypoxic regions, will then be quantified using immunohistochemistry at an advanced optical microscopy facility.	Tumour biopsy within 24-48h after administration of doxorubicin (in consenting patients with disease amenable to biopsy)	No